LOGIN
OTA 2023: TXA on Blood Loss & Transfusion Rates for Extracapsular Hip Fractures
October 2023
OTA 2023: TXA on Blood Loss & Transfusion Rates for Extracapsular Hip Fractures
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Tranexamic Acid Administered at Time of Hospital Admission Does Not Decrease Transfusion Rates or Blood Loss for Extracapsular Hip Fractures: A Double-Blinded Randomized Clinical Trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
128 patients with AO/OTA 31-A fractures were randomized to receive either intravenous tranexamic acid (IV TXA; n=64), or IV saline (n=64). The primary outcome of interest was rate of red blood cell (RBC) transfusion on postoperative days (POD) 1-4. Secondary outcomes of interest included estimated blood loss, venous thromboembolic events (VTEs), stroke, myocardial infarction, all-cause 90-day read...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.